Literature DB >> 23838499

A UK national survey of breast surgeons on primary endocrine therapy of early operable breast cancer.

S Wylie1, D Ravichandran.   

Abstract

INTRODUCTION: A significant proportion of elderly breast cancer patients in the UK have no surgical treatment recorded and appear to be treated with primary endocrine therapy (PET) only. Despite this, PET remains one of the poorly studied areas in breast cancer therapy and very little is known about the practice of PET in the UK.
METHODS: A questionnaire comprising 14 questions relevant to PET was sent to 489 breast surgeons who were members of the UK Association of Breast Surgery and returned questionnaires were analysed.
RESULTS: Overall, 228 questionnaires (47%) were returned. The vast majority (93%) of surgeons who responded use PET in early operable breast cancer in elderly women unfit for surgery or owing to patient preference but 7% would recommend PET to fit elderly patients. Most (76%) use letrozole. The percentage of elderly patients treated with PET varied from <10% to 70% between surgeons. The majority (77%) of respondents had not formally audited the outcome of their PET patients and over 70% underestimated the expected survival of an 80-year-old woman.
CONCLUSIONS: Most UK breast surgeons use PET in elderly patients with surgically resectable breast cancer. While most use it in unfit, frail patients, a minority would treat even fit elderly women with PET. Most surgeons have not formally audited the outcome of their patients treated with PET and underestimate the expected survival of elderly patients, which might have an impact on their decision to offer PET rather than surgery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23838499      PMCID: PMC4165139          DOI: 10.1308/003588413X13629960045832

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  11 in total

Review 1.  Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.

Authors:  Rob Riemsma; C A Forbes; A Kessels; K Lykopoulos; M M Amonkar; D W Rea; J Kleijnen
Journal:  Breast Cancer Res Treat       Date:  2010-06-10       Impact factor: 4.872

2.  Early and locally advanced breast cancer: diagnosis and treatment National Institute for Health and Clinical Excellence guideline 2009.

Authors:  J Yarnold
Journal:  Clin Oncol (R Coll Radiol)       Date:  2009-01-23       Impact factor: 4.126

3.  Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Authors:  Meredith M Regan; Patrick Neven; Anita Giobbie-Hurder; Aron Goldhirsch; Bent Ejlertsen; Louis Mauriac; John F Forbes; Ian Smith; István Láng; Andrew Wardley; Manuela Rabaglio; Karen N Price; Richard D Gelber; Alan S Coates; Beat Thürlimann
Journal:  Lancet Oncol       Date:  2011-10-20       Impact factor: 41.316

4.  Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.

Authors:  W Eiermann; S Paepke; J Appfelstaedt; A Llombart-Cussac; J Eremin; J Vinholes; L Mauriac; M Ellis; M Lassus; H A Chaudri-Ross; M Dugan; M Borgs
Journal:  Ann Oncol       Date:  2001-11       Impact factor: 32.976

5.  Elderly women with breast cancer often die due to other causes regardless of primary endocrine therapy or primary surgical therapy.

Authors:  M J Traa; C M E M Meijs; M A C de Jongh; E C H M van der Borst; J A Roukema
Journal:  Breast       Date:  2011-02-15       Impact factor: 4.380

6.  Undertreatment strongly decreases prognosis of breast cancer in elderly women.

Authors:  Christine Bouchardy; Elisabetta Rapiti; Gérald Fioretta; Paul Laissue; Isabelle Neyroud-Caspar; Peter Schäfer; John Kurtz; André-Pascal Sappino; Georges Vlastos
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

7.  Increase in response rate by prolonged treatment with neoadjuvant letrozole.

Authors:  J Michael Dixon; Lorna Renshaw; E Jane Macaskill; Oliver Young; Juliette Murray; David Cameron; Gillian R Kerr; Dean B Evans; William R Miller
Journal:  Breast Cancer Res Treat       Date:  2008-02-09       Impact factor: 4.872

8.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Authors:  Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes
Journal:  Lancet Oncol       Date:  2010-11-17       Impact factor: 41.316

9.  Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre.

Authors:  B M Syed; W Al-Khyatt; S J Johnston; D W M Wong; L Winterbottom; H Kennedy; A R Green; D A L Morgan; I O Ellis; K L Cheung
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

10.  Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: cochrane review.

Authors:  D Hind; L Wyld; M W Reed
Journal:  Br J Cancer       Date:  2007-02-06       Impact factor: 7.640

View more
  4 in total

Review 1.  Primary Endocrine Therapy in Older Women with Breast Cancer.

Authors:  R M C Pepping; J E A Portielje; W van de Water; N A de Glas
Journal:  Curr Geriatr Rep       Date:  2017-10-19

2.  Defer surgery in operable breast cancer: how long is too long?

Authors:  Sacha Roberts; Aram Rojas; Giulia DiRaimo; Melanie Orlando; Mahir Gachabayov; Maria Castaldi
Journal:  Breast Cancer       Date:  2021-10-18       Impact factor: 3.307

3.  Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: a National Cancer Database analysis.

Authors:  D Boyce-Fappiano; I Bedrosian; Y Shen; H Lin; O Gjyshi; A Yoder; S F Shaitelman; W A Woodward
Journal:  NPJ Breast Cancer       Date:  2021-07-05

4.  Why are older women not having surgery for breast cancer? A qualitative study.

Authors:  Anne Marie Sowerbutts; Jane Griffiths; Chris Todd; Katrina Lavelle
Journal:  Psychooncology       Date:  2015-02-02       Impact factor: 3.894

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.